Your browser doesn't support javascript.
loading
Choice of SARS-CoV-2 diagnostic test: challenges and key considerations for the future.
Baldanti, Fausto; Ganguly, Nirmal K; Wang, Guiqiang; Möckel, Martin; O'Neill, Luke A; Renz, Harald; Dos Santos Ferreira, Carlos Eduardo; Tateda, Kazuhiro; Van Der Pol, Barbara.
Afiliação
  • Baldanti F; Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.
  • Ganguly NK; Indian Council of Medical Research, New Delhi, India.
  • Wang G; The Center for Liver Diseases, Peking University First Hospital, Beijing, China.
  • Möckel M; Charité - Universitätsmedizin, Berlin, Germany.
  • O'Neill LA; Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • Renz H; Institute of Laboratory Medicine and Pathobiochemistry, Molecular Diagnostics, Philipps University Marburg, University Hospital Giessen and Marburg GmbH, Giessen, Germany.
  • Dos Santos Ferreira CE; Department of Clinical Immunology and Allergology, I.M. Sechenov First Moscow State Medical University, Moscow, Russia.
  • Tateda K; Albert Einstein Hospital, São Paulo, Brazil.
  • Van Der Pol B; Department of Microbiology and Infectious Diseases, Toho University School of Medicine, Tokyo, Japan.
Crit Rev Clin Lab Sci ; 59(7): 445-459, 2022 11.
Article em En | MEDLINE | ID: mdl-35289222
A plethora of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostic tests are available, each with different performance specifications, detection methods, and targets. This narrative review aims to summarize the diagnostic technologies available and how they are best selected to tackle SARS-CoV-2 infection as the pandemic evolves. Seven key settings have been identified where diagnostic tests are being deployed: symptomatic individuals presenting for diagnostic testing and/or treatment of COVID-19 symptoms; asymptomatic individuals accessing healthcare for planned non-COVID-19-related reasons; patients needing to access emergency care (symptom status unknown); patients being discharged from healthcare following hospitalization for COVID-19; healthy individuals in both single event settings (e.g. airports, restaurants, hotels, concerts, and sporting events) and repeat access settings (e.g. workplaces, schools, and universities); and vaccinated individuals. While molecular diagnostics remain central to SARS-CoV-2 testing strategies, we have offered some discussion on the considerations for when other tools and technologies may be useful, when centralized/point-of-care testing is appropriate, and how the various additional diagnostics can be deployed in differently resourced settings. As the pandemic evolves, molecular testing remains important for definitive diagnosis, but increasingly widespread point-of-care testing is essential to the re-opening of society.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Crit Rev Clin Lab Sci Assunto da revista: TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Revista: Crit Rev Clin Lab Sci Assunto da revista: TECNICAS E PROCEDIMENTOS DE LABORATORIO Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Itália